Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Operating Margin: 2024-2025

Historic Operating Margin for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Sep 2025 value amounting to -258.26%.

  • Monte Rosa Therapeutics' Operating Margin rose 2957.00% to -258.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.69%, marking a year-over-year change of. This contributed to the annual value of -107.26% for FY2024, which is N/A change from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Operating Margin stood at -258.26%, which was down 285.12% from -67.06% recorded in Q2 2025.
  • Monte Rosa Therapeutics' Operating Margin's 5-year high stood at 51.85% during Q1 2025, with a 5-year trough of -3,284.49% in Q1 2024.
  • Over the past 2 years, Monte Rosa Therapeutics' median Operating Margin value was -258.26% (recorded in 2025), while the average stood at -645.66%.
  • Data for Monte Rosa Therapeutics' Operating Margin shows a peak YoY skyrocketed of 333,634bps (in 2025) over the last 5 years.
  • Over the past 2 years, Monte Rosa Therapeutics' Operating Margin (Quarterly) stood at 21.44% in 2024, then spiked by 2,957bps to -258.26% in 2025.
  • Its Operating Margin was -258.26% in Q3 2025, compared to -67.06% in Q2 2025 and 51.85% in Q1 2025.